Health-Related Quality of Life in Patients with Alpha-1 Antitrypsin Deficiency: The French Experience

Figures & data

Table 1.  Baseline characteristics of patients (n = 273)

Variable
Age, mean (SD)	51.8 (11.1)
Age, years
≤50	128 (46.9)
51-55	36 (13.2)
56-60	43 (15.8)
>60	66 (24.2)
Females	101 (37)
Smoking status
Current smokers	23 (8.4)
Never smokers	33 (12.1)
Pack-years, mean (SD)	20.2 (16.5)
MRC dyspnea scale
1	10 (3.7)
2	108 (39.6)
3	86 (31.5)
4	52 (19.1)
5	15 (5.5)
Body mass index, kg/m^2, mean (SD)	22.7 (4.0)
GOLD Stage
1	0
2	67 (24.5)
3	112 (41.0)
4	76 (27.8)
GOLD 2011 Stage
A	17 (6.2%)
B	43 (15.8%)
C	16 (5.9%)
D	197 (72.2%)
Exacerbations
In the year before inclusion (median)	1
At least one exacerbation during the year before inclusion	153 (56.0)
Decompensations
In the year before inclusion (median)	0
At least one decompensation during the year before inclusion	55 (20.2)
FEV1 (% predicted), mean (SD)	40.5 (15.7)
TLC (% predicted), mean (SD)	129 (21.9)
DLCO (% predicted), mean (SD)	43.5 (18.2)
6-min walking distance, mean (SD)	434.3 (133.6)
Treatment
Inhaled corticosteroids	228 (85.5)
Long-acting β2-agonists	249 (91.2)
Long-acting anti-cholinergic agents	207 (75.8)
Augmentation therapy	130 (47.6)
Pulmonary rehabilitation in the year before inclusion	64 (23.4)
Oxygen required at rest	88 (32.2)
St. George Respiratory Questionnaire score, mean (SD)
Activity	63.6 (22.3)
Impact	39.4 (22.2)
Symptoms	52.5 (22.0)
Total	49.0 (20.0)

Data are no. (%) unless indicated.

MRC scale: Medical Research Council scale. Gold, Global Initiative for Chronic Obstructive Lung Disease; FEV₁, forced expiratory volume in 1 sec; TLC, total lung capacity; DLCO, diffusing lung capacity.

Figure 1.  6 minutes walking distance, Fletcher’s Dyspnea scale, and SGRQ according to the GOLD 2006 classification.